Dr. Ho: CAR-T cell therapy uses an antibody as a guide or sensor to locate the immune cells—in this case, T-cells—to the tumors then kill tumors using T-cell signaling. So therefore, CAR-T cells use both antibody specifi...
Significant advances have been made in chimeric antigen receptor T (CAR-T)-cell therapy for the treatment of recurrent or refractory B-cell hematologic malignancies. However, CAR-T-cell therapy has not yet achieved comparable success in the management of aggressive T-cell malignancies. This article...
Serious adverse reactions, moderate anti-tumor activity, allergen withdrawal, antigen escape, limited tumor infiltration, and trafficking are major barriers to successful CAR T-cell therapy. This review is a brief synopsis of the development of CAR T-cell therapy for MCL....
Chimeric antigen receptor (CAR)-T cell adoptive immunotherapy is a promising cancer treatment that uses genetically engineered T cells to attack tumors. However, this therapy can have some adverse effects. CAR-T cell-derived exosomes are a potential alte
CAR T-Cell Therapy Associated with Unique, Acute Adverse Events Requiring Vigilant MonitoringDavila, Marco L.Journal of Oncology Navigation & Survivorship
the ZUMA-2 clinical trial. Serious adverse reactions, moderate anti-tumor activity, allergen withdrawal, antigen escape, limited tumor infiltration, and trafficking are major barriers to successful CAR T-cell therapy. This review is a brief synopsis of the development of CAR T-cell therapy for ...
Chimeric antigen receptor (CAR)-T cell therapy demonstrates substantial efficacy in various hematological malignancies. However, its application in solid tumors is still limited. Clinical studies report suboptimal outcomes such as reduced cytotoxicity of
The application of chimeric antigen receptor T-cell therapy in central nervous system tumors has significantly advanced; however, challenges pertaining to the blood-brain barrier, immunosuppressive microenvironment, and antigenic heterogeneity continue t
//doi.org/10.1186/s12929-023-00982-8 REVIEW Open Access Complete spectrum of adverse events associated with chimeric antigen receptor (CAR)‑T cell therapies Chieh Yang1, John Nguyen2 and Yun Yen3* Abstract Chimeric antigen receptor (CAR)-T cell therapies have been...
1.Yáñez L, Alarcón A, Sánchez-Escamilla M, Perales MA. How I treat adverse effects of CAR-T cell therapy. ESMO Open. 2020;4(Suppl 4):e000746. 2.Rejeski K, Subklewe M, Aljurf M, Bachy E, Balduzzi A, Ba...